Spark therapeutics, inc. (ONCE)
CashFlow / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-66,602

-64,230

-54,358

-65,257

-47,357

80,165

-46,373

-61,821

-65,012

-74,360

-52,289

-36,837

-32,562

-28,676

-25,576

-6,154

-16,900

-14,336

-9,733

-9,015

-6,756

-4,168

-4,383

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash income

-

-

-

-

-

-

-

127

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash income

-

-

-785

-

-

-

-75

-1,127

62

231

303

12

-180

-180

-180

-180

-53

208

208

-

-

-

-

Depreciation and amortization expense

2,521

2,587

2,432

2,080

1,695

1,618

1,507

-

-

-

1,031

986

957

911

744

487

448

426

370

-

-

-

-

Loss on disposal of property and equipment

-1,626

0

0

20

-64

0

-59

-32

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

-

3,397

1,750

3,070

387

11,132

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

11,034

11,715

11,798

10,882

11,363

14,118

12,223

7,538

15,446

9,360

9,029

7,235

5,788

6,648

4,865

5,093

3,020

2,900

2,558

746

794

1,043

389

Unrealized (gain) loss on equity investments

-13

-422

-211

-9,369

1,672

2,255

364

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash income tax benefit

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest (income) expense

-83

-91

-95

-

473

337

597

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Inventory

922

837

4,457

4,899

8,064

7,114

5,560

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-673

-32,722

5,334

29,769

4,305

-268

1,527

656

-1,167

1,699

1,969

1

-338

-260

860

992

-214

335

514

87

266

159

156

Trade and other receivables

-25,181

32,880

-26,925

33,811

-11,636

4,044

13,282

-

-

-

-10,700

15,752

37

171

-15,726

15,693

318

263

425

-

-

-

-

Accounts payable and accrued expenses

7,696

-186

-3,841

9,580

7,146

359

-8,382

12,142

-4,003

7,532

-2,690

5,796

6,208

-839

-1,146

1,397

4,475

2,308

870

-0

419

1,189

722

Deferred rent

-

-

-

-

-

-

-

-870

0

-1,174

3,654

0

0

0

0

-

-

-

-

-

-

-

-

Deferred revenue

0

0

-5,161

55,000

-1,841

-20,871

115,743

7,591

-1,899

-1,484

-1,274

-1,301

-1,302

-1,288

-1,288

-1,698

-1,302

-1,288

-2,274

-

-

-

-

Other liabilities

267

630

376

537

104

371

-371

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-18,375

-49,974

-32,099

-42,527

-32,272

-48,765

53,001

-26,743

-51,915

-42,760

-33,118

-28,595

-20,791

-23,336

-7,718

-17,741

-10,415

-10,380

-8,939

15,174

-805

-555

-3,428

Cash flows from investing activities:
Payment for license agreement

0

0

0

0

0

0

2,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment for acquisition, net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-0

0

3

5,907

0

0

0

0

-

-

-

-

Purchases of marketable securities

-129

809

75,343

170,420

131,143

118,544

110,882

-

-

-

24,225

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

108,289

101,359

96,016

164,106

132,055

125,439

94,673

-

-

-

24,780

-

-

-

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

7,444

5,945

4,288

18,901

6,791

3,988

4,141

759

1,674

4,991

2,230

1,065

1,813

1,178

4,473

1,444

565

826

1,685

6,733

4,478

448

37

Net cash provided by investing activities

100,974

94,605

16,385

-25,515

-5,879

112,907

-22,350

-26,095

-230,789

50,827

-1,675

-4,132

-115,869

-155,136

-10,381

-1,444

-565

-826

-1,685

-6,733

-4,478

-448

-37

Cash flows from financing activities:
Proceeds from exercise of options

1,374

4,929

11,607

2,002

1,383

10,414

1,332

3,689

11,876

1,734

3,434

757

789

848

196

1,023

92

0

0

-

-

-

-

Purchase of treasury stock

810

1,671

15,314

163

478

1,038

1,756

40

162

471

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Series A convertible preferred units

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,861

Proceeds from public offerings of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-157

170,470

-

-

-

-

Proceeds from issuance of common stock under ESPP

0

0

563

-1,567

805

0

762

-138

380,008

0

0

-

-

-

-657

-

-

-

-

-

-

-

-

Payments on long-term debt

1,581

80

80

79

78

78

77

76

76

75

75

0

24

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-1,017

3,178

-3,224

1,760

51,632

9,298

261

3,435

392,292

1,188

3,359

1,047

2,249

128,529

-461

100,557

92

-157

170,470

-1,147

-565

72,728

4,861

Effect of exchange rate changes on cash and cash equivalents and restricted cash

-54

-17

8

-28

-10

-41

27

-

-

-

6

-

-

-

0

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents and restricted cash

81,528

47,792

-18,930

-66,310

13,471

73,399

30,939

-49,686

109,622

9,317

-31,428

-31,692

-134,411

-49,942

-18,561

81,371

-10,888

-11,364

159,845

7,294

-5,849

71,725

1,396

Supplemental disclosure of cash flow information:
Deferred financing costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-157

157

-191

771

278

10

Property and equipment purchases included in accounts payable and accrued expenses

2,373

-33

9,069

-8,428

13,380

3,286

1,280

1,933

-566

-1,364

2,786

58

-618

893

348

1,848

587

-309

557

-2,350

666

2,772

59

One Drexel Plaza lease cost included in other liabilities

-

0

0

-574

355

359

363

34,986

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-